Background: Observational postmarketing studies are important to assess vaccine effectiveness (VE). We estimated VE from the bivalent human papillomavirus (HPV) vaccine against HPV positivity of vaccine and nonvaccine types in a high-risk population.
Methods: We included all vaccine-eligible women from the PASSYON study, a biennial cross-sectional survey in Dutch sexually transmitted infection clinics. Vaginal swabs were analyzed using a polymerase chain reaction-based assay (SPF10-LiPA(25)) able to detect the 12 high-risk HPV (hrHPV) types 16/18/31/33/35/39/45/51/52/56/58/59. We compared hrHPV positivity between self-reported vaccinated (>= 1 dose) and unvaccinated women, and estimated VE by a logistic mixed model.
Results: We included 1087 women of which 53% were hrHPV positive and 60% reported to be vaccinated. The adjusted pooled VE against HPV-16/18 was 89.9% (81.7%-94.4%). Moreover, we calculated significant VE against nonvaccine types HPV-45 (91%), HPV-35 (57%), HPV-31 (50%), and HPV-52 (37%). Among women who were offered vaccination 5/6 years ago, we estimated similar VE against HPV-16/18 (92%) and all hrHPV types (35%) compared to women who were offered vaccination
Conclusion: We demonstrated high VE of the bivalent vaccine against HPV-16/18 and cross-protection against HPV45/ 35/31/52. Protection against HPV-16/18 was sustained up to 6 years postvaccination.
- human papillomavirus
- human papillomavirus vaccine
- vaccine effectiveness
- public health
- HUMAN-PAPILLOMAVIRUS VACCINATION
- HPV-16/18 AS04-ADJUVANTED VACCINE
- INVASIVE CERVICAL-CANCER
- BLIND PATRICIA TRIAL
- OF-STUDY ANALYSIS
- INTRAEPITHELIAL NEOPLASIA
- PCR ASSAY